RxDoctor Payments DataLook up a doctor →

Gregorio Cortes-Maisonet

General Practice · San Juan, PRNPI 1639151616

Payments from drug & device makers

$12,769,765in general payments, 2019–2025

Across 1,508 payments — averaging $8468.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$7M
  • E.r. Squibb & Sons, L.L.C.$1.3M
  • Eli Lilly$1.2M
  • AbbVie$1.1M
  • Modernatx, Inc.$955K
  • Takeda Pharmaceuticals U.S.A., Inc.$350K
  • plus $961K from 17 others
$202,903in research payments, 2019–2025

Across 90 payments — averaging $2254.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$145K
  • Eli Lilly Export S.A. Puerto Rico Branch$50K
  • AbbVie$8K

What the payments were for

  • Consulting fees$1,0504%
  • Travel & lodging$20,26678%
  • Food & beverage$4,63718%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,769,765 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$18,710
SynjardyEmpagliflozin/Metformin Hcl11$17,371
RybelsusSemaglutide13$14,587
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,724
Synjardy XrEmpagliflozin/Metformin Hcl13$9,261
SynthroidLevothyroxine Sodium44$3,709
Pentoxifylline30$1,501
LantusInsulin Glargine,hum.Rec.Anlog14$1,322
Atorvastatin Calcium83$1,004
Levothyroxine Sodium50$791
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$776
FenofibrateFenofibrate Nanocrystallized26$744
Losartan Potassium71$741
Glimepiride13$713
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide14$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$296$33,29732 claims
Boehringer IngelheimSynjardy, Synjardy Xr$155,800$26,63224 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$38$12,04626 claims
AbbVieSynthroid$1,067,515$3,70944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →